Marinomed Biotech AG
VSE:MARI
Intrinsic Value
The intrinsic value of one MARI stock under the Base Case scenario is 58.59 EUR. Compared to the current market price of 41.8 EUR, Marinomed Biotech AG is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Marinomed Biotech AG
Fundamental Analysis

Revenue & Expenses Breakdown
Marinomed Biotech AG
Balance Sheet Decomposition
Marinomed Biotech AG
Current Assets | 4.2m |
Cash & Short-Term Investments | 911.5k |
Receivables | 2.5m |
Other Current Assets | 812.8k |
Non-Current Assets | 7.1m |
PP&E | 5.8m |
Intangibles | 1.4m |
Other Non-Current Assets | 4.5k |
Free Cash Flow Analysis
Marinomed Biotech AG
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Marinomed Biotech AG
Revenue
|
6.4m
EUR
|
Cost of Revenue
|
-5.4m
EUR
|
Gross Profit
|
1m
EUR
|
Operating Expenses
|
-6.5m
EUR
|
Operating Income
|
-5.4m
EUR
|
Other Expenses
|
-8.7m
EUR
|
Net Income
|
-14.1m
EUR
|
MARI Profitability Score
Profitability Due Diligence
Marinomed Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Marinomed Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
MARI Solvency Score
Solvency Due Diligence
Marinomed Biotech AG's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Score
Marinomed Biotech AG's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MARI Price Targets Summary
Marinomed Biotech AG
According to Wall Street analysts, the average 1-year price target for MARI is 42.84 EUR with a low forecast of 42.42 EUR and a high forecast of 44.1 EUR.
Dividends
Current shareholder yield for MARI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one MARI stock under the Base Case scenario is 58.59 EUR.
Compared to the current market price of 41.8 EUR, Marinomed Biotech AG is Undervalued by 29%.